Enanta And AbbVie On EDP-305: Assessing Any Future Collaboration In Liver Diseases [Seeking Alpha]
Enanta Pharmaceuticals, Inc. (ENTA)
Last enanta pharmaceuticals, inc. earnings: 2/6 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.enanta.com/investor-overview
Company Research
Source: Seeking Alpha
Enanta And AbbVie On EDP-305: Assessing Any Future Collaboration In Liver Diseases Summary Liver Therapy Forum weekly digest provides an overview on what’s happening in liver diseases in 2019. This week focuses on Enanta Pharmaceuticals. Enanta has a license agreement with AbbVie for commercialization of its HCV therapeutics. My outlook on AbbVie’s potential future plans for Enanta beyond acquisition of Allergan. EDP-305 is a new generation FXR agonist in Phase 2 clinical studies for cholestatic liver disease, primary biliary cholangitis, and NASH, I provide updates. Market Assessment Enanta ( ENTA ABBV recently planned AGN CEO noted Before that could happen, Enanta has to demonstrate histological clinical efficacy for EDP-305 in NASH which is a few years away. This is because the ongoing 12-week Phase 2 study is expected to reveal the safety and tolerability Mainly, the prototype FXR agonist, obeticholic acid by Intercept ( ICPT GILD NVS As to EDP-305 on the Phase 2 PBC (INTREPID) st
Show less
Read more
Impact Snapshot
Event Time:
ENTA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENTA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENTA alerts
High impacting Enanta Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ENTA
News
- The past three years for Enanta Pharmaceuticals (NASDAQ:ENTA) investors has not been profitable [Yahoo! Finance]Yahoo! Finance
- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.MarketBeat
- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $22.00 price target on the stock.MarketBeat
- Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains? [Yahoo! Finance]Yahoo! Finance
- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $22.00 price target on the stock.MarketBeat
ENTA
Earnings
- 8/5/24 - Beat
ENTA
Sec Filings
- 11/14/24 - Form SC
- 10/17/24 - Form SC
- ENTA's page on the SEC website